Clinical Experience of Transurethral Needle Ablation (TUNA) for the Treatment of Benign Prostatic Hyperplasia with Low Compliance to Medication and High Risk Operative Morbidity and Mortality.
- Author:
Yong Wan SEONG
1
;
Eun Yong CHOI
;
Duk Kyo KIM
Author Information
1. Department of Urology, Hanil Hospital, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
TUNA;
BPH;
Morbidity
- MeSH:
Anesthesia, Local;
Compliance*;
Humans;
Mortality*;
Needles*;
Prospective Studies;
Prostate;
Prostatic Hyperplasia*;
Tuna
- From:Korean Journal of Urology
2001;42(10):1096-1100
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: We investigated the efficacy of transurethral needle ablation (TUNA) of prostate for benign prostatic hyperplasia (BPH) in patients with low compliance to medical therapy and high risk operative morbidity and mortality. MATERIALS AND METHODS: Total 38 patients with BPH and low compliance to medical therapy and high risk operative morbidity and mortality were treated with TUNA under the local anesthesia and evaluated prospectively using the international prostate symtom score (IPSS), Qmax, satisfaction score and postvoid residuals (PVRs), and followed for 3 months after treatment. RESULTS: The mean pretreatment symptom score was 24.82+/-5.76. At 1 and 3 months after treatment, the mean symptom score was decreased to 13.63+/-7.07 and 9.21+/-6.28, respectively (p<0.01). The mean pretreatment satisfaction score was 4.63+/-0.85. It was decreased to 2.84+/-1.26, 1.92+/-1.34 at 1, 3 months (p<0.01). The mean pretreatment Qmax was 5.26+/-3.37mL/s. It was increased to 9.53+/-4.54mL/s, 11.97+/-4.52mL/s at 1, 3 months (p<0.01). The mean pretreatment PVRs were 131.85+/-123.05mL. It was decreased to 49.68+/-38.28mL, 26.77+/-17.92mL at 1, 3 months (p<0.01). CONCLUSIONS: TUNA treatment in the management of BPH improved symptom scores, peak flow rates with lower morbidity. TUNA appears to be a useful alternative treatment for BPH in patients with low compliance to medical therapy and high risk operative morbidity and mortality.
